RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - MECCANISMI CELLULARI E MOLECOLARI DEL RIMODELLAMENTO CARDIACO E NUOVE STRATEGIE TERAPEUTICHE.
• 2 - Markers clinici, genetici e molecolari della suscettibilità alla fibrillazione atriale: verso un approccio integrato della prevenzione e terapia dell'aritmia e delle sue complicanze.
• 3 - Meccanismi di danno e protezione nel miocardio ischemico
• 4 - Nuove prospettive nella fibrillazione atriale: dalla ricerca di base all'approccio terapeutico farmacologico e chirurgico.
• 5 - Determinanti genetici e molecolari del ruolo della COX-2 nell'aterotrombosi.
• 6 - Meccanismi molecolari dello sviluppo del danno d'organo nella malattia ipertensiva.
• 7 - Danno cardio-vascolare precoce in bambini ed adolescenti obesi :la identificazione di markers di rischio metabolici e/o genetici rende possibile la diagnosi precoce e può migliorare la qualità della vita futura.
• 8 - BETA AMILOIDE: IL PRINCIPALE RESPONSABILE DELLA NEURODEGENERAZIONE NELLA MALATTIA DI ALZHEIMER O UN NUOVO NEUROMODULATORE?
• 9 - EFFETTI DEGLI INIBITORI DELLA FOSFODIESTERASI TIPO 5 (PDE5i) SULLA FUNZIONE SESSUALE, ENDOCRINA E VASCOLARE
• 10 - Effetti di rosiglitazone e metformina sullo sviluppo e la progressione dell'insufficienza cardiaca cronica in un modello di insulino-resistenza e scompenso cardiaco

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze biologiche
  • BIOCHIMICA CLINICA E BIOLOGIA MOLECOLARE CLINICA
• Area scientifico disciplinare: Scienze mediche
  • MEDICINA INTERNA
  • MALATTIE DELL'APPARATO CARDIOVASCOLARE

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material A01N63/00; food compositions A21, A23; medicinal preparations A61K; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS (preservation of living parts of humans or animals A01N1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (micro-biological testing media C12Q)
• HUMAN NECESSITIES
  • MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing into special physical form A61J [N: mechanical aspects]; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; compounds per se C01, C07, C08, C12N; soap compositions C11D; micro-organisms per se C12N) [C0203]
    • THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

Classificazione geografica

• Regione: Sicilia

Bibliografia

-Massie BM et al. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management.Am Heart J 1997,133:703
-Centers for Disease Control and Prevention: National Vital Statistics Report,Vol 47.Hyattsville,National Center for Health Statistics 1999
-ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult.JACC 2001,1-56
-Licata G et al.Left ventricular function response to exercise in normtensive obese subjects: influence of degree and duration of obesity.Int J Cardiol 1992,37:223-230.
-Scaglione R et al.Left ventricular diastolic and systolic function in normotensive obese subjects: influence of degree and duration of obesity.European heart Journal 1992,13: 738-742.
-Cowie MR et al.Value of natriuretic peptide in assessment of patients with possible new heart failure in primary care.Lancet 1997,350:1349-1353
-Dries DL et al.Brain natriuretic peptide as bridge to therapy of heart failure Lancet 2000,355:1112-1116
-Dao Q et al.Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting.JACC 2001,37:379-385
-Remme WJ et al.Guidelines for the diagnosis and treatment of chronic heart failure.Eur Heart J 2001,22:1527-1560
-Baumgarten G et al. Cytokines as emerging targets in the treatment of heart failure.Trend Cardiovasc Med 2000,10:216-223
-Mann DL.Recent insights into the role of tumor necrosis factor in the failing heart.Heart Fail Rev 2001,6:71-80
-Kell R et al.Do cytokines enable risk stratification to be improved in NYHA functional class III patients?Comparison with other potential predictors of prognosis.Eur Heart J 2002,2370-78
-Laviades C et al.Trasforming Growth Factor beta in hypertensives with cardiorenal damage.Hypertension 2000,36:517-522
-Border WA et al.Interactions of trasforming growth factor beta and angiotensin II in renal fibrosis. Hypertension 1998,31:181-188
-Li B et al.TGF-beta1 DNA polymorphisms protein levels and blood pressure.Hypertension 1999,33:271-275
-Cambien F et al. Polymorphisms of the trasforming growth factor beta 1 gene in relation to myocardial infarction and blood pressure: the Etude Cast-Temoin de l'Infarcteur du Myocarde (ECTIM study)Hypertension 1996,28:881-887
-Kuwahara F et al. Transforming growth factor beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats.Circulation 2002,106:130-135.
-Tsokos GC, Fleming S.D.Autoimmunity, complement activation, tissue injury and reciprocal effects.Current directions in autoimmunity 7:149-164(2004)
-Acosta J et al.Complement and complement regulatory proteins as potential molecular targets for vascuilar diseases. Current pharmaceutical Design 10: 203-211 (2004)
-De Zwann C et al.Prevention of cardiac cell injury during acute myocardial infarction:possible role for complement inhibition.American Journal of Cardiovacular Drugs 3:245-251(2003)
-Cowell RM et al. Complement activation contributes to hypoxic-ischemic brain injury in neonatal rats. Journal of Neuroscience 23:9459-9468 (2003)
-De Vries B et al.Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils. Journal of Immunology 170:3883-3889 (2003)
-Riedemann NC and Ward P.A. Complement in ischemia-reperfusion. American Journal of Pathology 162:363-367 (2003).
-Bhole D, Stahl GL. Therapeutic potential of targeting the complement cascade in critical care medicine. Critical Care Medicine 31: S104. (2003)
-Thurman JM et al.Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. Journal of Immunology 170:1517-1523(2003)
-Schwertz H et al.Two-dimensional analysis of myocardial protein expression following myocardial ischemia and reperfusion in rabbits. Proteomics 2:988-995(2002)
-Raine AEG et al. Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N.Engl.J.Med.1986; 315: 533-537.
-Gottlieb SS et al.Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J.Am.Coll.Cardiol. 1989; 13: 1534-1539.
-Volpe M et al.Failure of atrial natriuretic factor to increase with saline load in patients with dilated cardiomyopathy and mild heart failure. J.Clin.Invest. 1991; 88: 1481-1489.
-Volpe M et al.Abnormalities of sodium handling and of cardiovascular adapatations during high salt diet in patients with mild heart failure. Circulation 1993; 88: 1620-1627.
-Volpe M et al. Angiotensin converting enzyme inhibition restores cardiac and hormonal responses to volume overload in patients with dilated cardiomyopathy and mild heart failure. Circulation 1992; 86: 1800-1809.
-Wang TJ et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N.Engl.J.Med. 2004; 350: 655-663.
-Rubattu S et al. The gene encoding atrial natriuretic peptide and the risk of human stroke. Circulation 1999; 100: 1722-1726.
-Rubattu S et al. Polymorphisms of the atrial natriuretic peptide gene and the risk of ischemic stroke in humans. Stroke 2004; 85: in press.
-Rademaker MT et al. Adrenomedullin and heart failure. Regul. Pept. 2003; 112: 51-60.
-Carmeliet P et al.Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7: 575-83., 2001.
-Edelberg JM et al.Platelet-derived growth factor-AB limits the extent of myocardial infarction in a rat model: feasibility of restoring impaired angiogenic capacity in the aging heart. Circulation 105: 608-13., 2002.
-Emanueli C et al.Rescue of impaired angiogenesis in spontaneously hypertensive rats by intramuscular human tissue kallikrein gene transfer. Hypertension 38: 136-41, 2001.
-Fredriksson JM et al.Norepinephrine induces vascular endothelial growth factor gene expression in brown adipocytes through a beta - adrenoreceptor/cAMP/protein kinase A pathway involving Src but independently of Erk1/2. J Biol Chem 275: 13802-11., 2000.
-Furchgott RF et al.The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288: 373-6., 1980.
-Iaccarino G et al. Beta(2)-adrenergic receptor gene delivery to the endothelium corrects impaired adrenergic vasorelaxation in hypertension.Circulation 106: 349-55., 2002.
-Isner JM. Myocardial gene therapy. Nature 415: 234-9., 2002.
-Keys JR et al. Gq-coupled receptor agonists mediate cardiac hypertrophy via the vasculature. Hypertension 40: 660-6., 2002.
-Kramer JM et al.Exercise and hypertension: a model for central neural plasticity. Clin Exp Pharmacol Physiol 29: 122-6., 2002.
-Leosco DG et al.EXERCISE RESTORES {beta}-ADRENERGIC VASORELAXATION IN AGED RAT CAROTID ARTERIES. Am J Physiol Heart Circ Physiol 13: 13, 2003.
Lindquist JM et al.Beta 3- and alpha1-adrenergic Erk1/2 activation is Src- but not Gi- mediated in Brown adipocytes. J Biol Chem 275: 22670-7., 2000.
-Murohara TT et a.Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 101: 2567-78., 1998.
-Risau W. Mechanisms of angiogenesis. Nature 386: 671-4., 1997.
-Sasaki H et al.Hypoxic preconditioning triggers myocardial angiogenesis: a novel approach to enhance contractile functional reserve in rat with myocardial infarction. J Mol Cell Cardiol 34: 335-48., 2002.
-Scarpace NT et al. Sympathetic nervous system: aging and exercise. South Med J 87: S42-6., 1994.
-Schaper W. Collateral circulation and diabetes. Circulation 99: 2224-6., 1999.
-Vane JR et al. Regulatory functions of the vascular endothelium. N Engl J Med 323: 27-36., 1990.

Parole Chiave

SCOMPENSO CARDIACO; ANGIOGENESI; CITOCHINE; PEPTIDI NATRIURETICI; INFIAMMAZIONE; GENETICA; TERAPIA GENICA